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Abstract
Aim: The effects of hepatocyte growth factor (HGF) on a non-invasive prostate cancer cell line (CAHPV-10), expressing 
cMET were studied, to mimic the possible effects neo-adjuvant androgen deprivation therapy may have in promoting 
tumour progression. 
Methods: Prostate epithelial cells and prostate cancer cells derived from cancer metastatic sites were analysed using 
cell culture assays, immunofluorescence, quantitative real-time polymerase chain reaction and western blotting, with or 
without HGF stimulation. 
Results: HGF significantly enhanced cell proliferation and induced cell scattering and invasion in CAHPV-10 cells 
compared to untreated controls. Active adenosine diphosphate-ribosylation factor 6 (ARF6) was found to be present in 
all metastatic prostate cancer cells, with levels highest in the most aggressive cell line, PC-3. Following stimulation with 
HGF, active ARF6 expression was substantially elevated in CAHPV-10 cells. 
Conclusion: These findings provide further molecular insight into the progression of prostate cancer and highlights 
potential issues for early prostate cancer therapeutic strategies.
Keywords: Prostate cancer, adenosine diphosphate-ribosylation factor 6, hepatocyte growth factor stimulation, androgen 
deprivation therapy
INTRODUCTION
Prostate cancer (PCa) is the most common cancer in men in the UK. Every year more than 35,000 cases of 
PCa are diagnosed, which equates to one man every 15 min and accounts for approximately 12% of all male 
deaths from cancer in the UK[1]. Androgens play a significant role in the growth and progression of PCa. The 
current therapy for locally advanced and metastatic disease is androgen deprivation therapy (ADT) either 
through orchidectomy, luteinising hormone releasing hormone or blockade through the androgen receptor 
(AR). For men with localised PCa, the two major treatment options are surgery by radical prostatectomy or 
radiotherapy. However, ADT is becoming increasingly important in the early stages[2]. ADT can be given 
in the neoadjuvant setting to reduce tumour size for improved excision during surgery or increase the ef-
fectiveness of radiotherapy[3]. ADT can also be given for men with localised PCa who are unfit for curative 
treatment (surgery or radiotherapy) or whose cancer has begun to progress and become symptomatic[4]. 
However, several studies have shown that following androgen suppression, expression of hepatocyte growth 
factor (HGF) or its receptor c-Met are elevated in prostate tissues[5,6]. Additional studies have also shown 
that suppression of the AR increases cMet expression in PCa cell lines[7,8] while increased c-Met expression 
is induced by removal of androgens in PCa cells[8]. HGF is a multifunctional cytokine, which in the prostate 
is secreted by prostate stromal cells and activates c-Met in a paracrine manner[9]. It is widely accepted that 
HGF dependent c-Met activation is involved in tumour development, including PCa, by inducing cell pro-
liferation[10] and activating stages of the metastatic cascade by stimulating migration[10,11], cell scattering[12], 
invasion[13] and angiogenesis[14]. 
It has been reported that serum levels of HGF correlate with stage of prostate malignancy. Thus, HGF serum 
levels are higher in men with localised PCa compared to healthy controls and further elevated in men with 
metastatic PCa compared to localised disease[15-17]. Plasma levels of HGF have also been documented as pre-
dicting PCa metastasis to the lymph nodes as well as recurrence following surgery[15]. Additionally, while c-
Met expression is linked to disease progression[5,18,19] elevated c-Met has been documented in localised PCa 
tissue when compared to healthy controls[20]. With the importance of HGF and c-Met in PCa well docu-
mented, it has been hypothesised that while current ADT potentially inhibits AR mediated cell proliferation 
and survival, it could also abolish its suppressive role on the HGF/c-Met pathway[7] and therefore may unin-
tentionally drive tumour progression. In addition, while there are a plethora of studies evaluating the effects 
of HGF in PCa[21-24], the majority focus on metastatic cell lines and hence advanced cancer. We, however, 
have sought to investigate the effect of HGF on a non-invasive cell line called CAHPV-10, known to express 
cMET[25] with the aim of ascertaining the molecular effects that may result due to ADT therapy on early 
state PCa and its role in promoting tumour progression and metastasis. 
Furthermore, HGF has been shown to activate adenosine diphosphate-ribosylation factor 6 (ARF6), which 
is a member of the Ras superfamily of GTPases[26,27]. Increased levels of activated ARF6 [ARF6-guanosine 
triphosphate (ARF6-GTP)] have been found to increase the invasive capacity of melanoma cells both in vi-
tro[28] and in vivo[29], while silencing ARF6, by small-interfering RNA, has been shown to inhibit the ability 
of breast cancer cells to invade through an artificial basement membrane[30]. While we have recently shown 
that ARF proteins are over-expressed in PCa tissue compared to normal control tissue[31], published stud-
ies on the presence of ARF6 in PCa are scant. The aims of the present investigation were to determine 1) if 
ARF6 is up-regulated in invasive PCa cells; 2) to investigate whether HGF stimulation correlates with active 
ARF6 expression in cells derived from non-invasive PCa. 
METHODS 
Cell culture 
Prostate epithelial cells (PNT2) and PCa cells derived from cancer metastasis to the lymph nodes (LNCaP) 
and bone (PC-3) were obtained from the European Collection of Cell Cultures. PCa cells derived from non-
Page 2 of 13                        Morgan et al . J Cancer Metastasis Treat 2018;4:46  I  http://dx.doi.org/10.20517/2394-4722.2018.19
invasive prostate cancer (CAHPV-10) and metastatic cancer to the brain (DU145) were purchased from the 
American Type Culture Collection. The cell lines were routinely cultured as described in Morgan et al.[32]. 
Gene expression analysis for ARF6 
Gene expression analysis was carried out as described in Morgan et al.[32] and the following ARF6 primers 
were used: 5’-TGTGGGTTTCAACGTGGAGAC-3’ and 5’-CAGTGTAGTAATGCCGCCAGAG-3’. β-actin 
and HPRT were used as reference genes, therefore the β-actin primers used were 5’-GATGGCCACGGCT-
GCTTC-3’ and 5’-TGCCTCAGGGCAGCGGAA-3’. HRPT primers used were 5’-GACTGTAGATTTTAT-
CAGACTGA-3’ and 5’-TGGATTATACTGCCTGACCAA-3’. 
Western blot analysis 
RIPA buffer (Sigma Aldrich, Dorset, UK) was used to extract the total protein, of which 30 μg was run a 12% 
tris-glycine PAGE gels (Bio-Rad Laboratories, Hemel Hempstead, UK). The western blot was carried out as 
described in Morgan et al.[32]. 
Primary mouse antibody to ARF6 (1:1000), as well as horseradish peroxidase conjugated secondary anti-
mouse were used (1:1000) (supplied in the Active ARF6 pull down and detection. β-actin (1:1000) (New Eng-
land Biolabs, Hertfordshire, UK) was a control for protein loading. 
Immunofluorescence for localisation of ARF6 
All prostate cells were seeded at 1 × 105 cells/mL onto sterile microscope slides. Slide preparation was carried 
out as previously described by Morgan et al.[32]. Immunofluorescence of ARF6 expression was performed by 
first incubating the slides with rabbit anti-ARF6 (1:1000 in 6% BSA/PBS) (abcam, Cambridge Science Park, 
Cambridge, UK) for 2 h at 37 °C. Following the washing steps to remove the primary antibody, secondary 
antibody anti-rabbit (Qdot525 Invitrogen, Paisley UK) (1:100 in 6% BSA/PBS) was added and the sample in-
cubated for 1 h at room temperature. The slides were again washed in water and fixed in ethanol (70%, 85% 
and 95%) for 2 min each. The AxioCam fluorescent microscope (Carl Zeiss Ltd, Hertfordshire, UK) was then 
used to analyse the slides. Negative controls (to rule out autofluorescence) were carried out by substituting 
the primary antibody for 1% BSA/PBS. 
GST pull down assay for activated ARF6 
All prostate cells were seeded in a T-175 cm3 flask and grown to 80% confluence. Total protein was extracted 
and ARF6-GTP isolated using the Active ARF6 pull down and detection kit (Thermo Scientific Langensel-
bold, Germany) according to manufacturer’s instructions. Briefly, cells were lysed using 1 mL lysis buffer 
and agitated on ice for 5 min before being scraped into a 2 mL tube and sheared through a 20 gauge needle 5 
times and centrifuged at 16,000 g at 4 °C for 15 min. 
The supernatant containing the total lysate was transferred to a new tube. An aliquot of the cell lysate was 
reserved for protein quantification using the Pierce BCA (Thermo Scientific, Langenselbold, Germany) and 
for detection of total ARF6 by western blot analysis. 
For detection of activated ARF6, the remaining lysate was added to a spin column containing GST-GGA3-
beads and incubated for 1 h at 4 °C with gentle rocking. The column was then centrifuged at 6000 g for 10-
30 s and washed with 400 µL of Lysis/Binding/Wash Buffer before centrifugation for a second time at 6000 g 
for 10-30 s. Twenty five microlitres of the elute (ARF6-GTP) and 25 µL of total protein lystate (total ARF6) 
were used for western blot analysis, as described above and experiments were performed in triplicate. 
HGF induced cell proliferation 
CAHPV-10 cells were seeded at 2000 cells/100 µL in 96 well plates and incubated at 37 °C for 24 h to allow 
for cell adherence and growth. Cells were then washed twice in phosphate buffered saline (PBS) (Invitrogen, 
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Paisley UK) and the cells grown for a further 24 h in serum starved medium (0.5% FCS). Hepatocyte growth 
factor (R&D systems, Minneapolis, USA) was then added to the cells at 10, 25, 50 and 100 ng/mL for 24 and 
48 h. PBS/0.1 BSA (Bovine Serum Albumen, Sigma Aldrich, Dorset, UK) was used as a negative control. 
Cell proliferation was assessed using the Cell 96® AQueous One Solution Cell Proliferation Assay (Promega, 
Southampton, UK) according to the manufacturers’ instructions. Four replicates for each HGF concentra-
tion were performed and the experiment repeated in triplicate. 
HGF induced cell invasion 
The invasive potential of CAHPV-10 cells following HGF treatment were assessed using a commercial cell 
invasion assay kit (Innocyte Cell Invasion Assay kit, Calbiochem, Merk, Middlesex, UK) utilising 8 µmol/L 
pore transwell inserts pre-coated with basement membrane extract. Briefly, the basement membrane extract 
was rehydrated by adding 300-400 µL of warm, serum-free medium for 30-60 min at room temperature. Fol-
lowing incubation the serum free medium was removed and 350 µL of a 1 × 106 cell suspension was added to 
each insert. Five hundred microlitres of medium containing either 10-100 ng/mL HGF or 0.1% BSA/PBS ve-
hicle control were added to both the upper and lower and the chambers of the transwell plate and incubated 
for 48 h. Following incubation, the inserts were removed and placed into unused 24-well plates containing 
500 µL of cell staining solution. Cells that had migrated through the basement membrane to the underside 
of the insert were then dislodged by tapping the insert against the bottom of the well before incubating for a 
further 30 min. Following incubation the inserts were removed and the wells containing the dislodged cells 
was incubated for an additional 30 min. Finally, 200 µL of the dislodged cell suspension were added to trip-
licate wells of a black 96-well plate (Thermo Scientific Langenselbold, Germany) and the fluorescence mea-
sured using an excitation wavelength of 485 nm and an emission wavelength of 520 nm. This experiment 
was performed in triplicate. 
HGF induced cell scattering 
CAHPV-10 and DU145 (positive control) cells were seeded at a density of 1 × 104 cells/mL of culture medium 
in 6-well plates. Cells were incubated until small colonies formed. Cells were then serum starved (0.5% FCS) 
for 24 h prior to stimulation with 10-100 ng/mL HGF for 24 and 48 h. Changes in cell morphology were 
observed using a light microscope (Carl Zeiss Ltd, Hertfordshire, UK) and representative colonies were pho-
tographed using a Canon Powershot A640. Negative controls using 0.1% BSA/PBS were also performed. The 
experiment was performed in triplicate. 
HGF stimulation of CAHPV-10 cells for activation of ARF6 
It was observed that CAHPV-10 cells, having very low levels of activated ARF6, were used to ascertain 
whether HGF stimulation could activate ARF6 in a non-invasive cell line. CAHPV10 cells were seeded as 
above and grown to 80% confluence. Cells were then treated with either 50 ng/mL HGF or 0.1% BSA/PBS 
vehicle control for 48 h. GST pull down assay was performed as described above. 
Statistical analysis 
To ascertain if our data was normally distributed a one sample Kolmogorov-Smirnov statistical test was 
performed. The resulting P > 0.05, indicated the data had a normal distribution. Parametric analysis was 
carried out including ANOVA test, Dunnett’s post hoc analysis to compare HGF treated with control cells 
and Tukey post hoc analysis was performed for multiple group comparisons. Statistical significance was 
considered for P < 0.05. For the invasion assay, Student T-test was performed and a P < 0.05 was considered 
significant. 
RESULTS 
HGF stimulation induced cell proliferation and invasion 
We wished to assess whether HGF could increase cell proliferation and invasion in a cell line derived from a 
non-invasive tumour. The results [Figure 1A and B] show PCa cell proliferation was significantly enhanced 
Page 4 of 13                        Morgan et al . J Cancer Metastasis Treat 2018;4:46  I  http://dx.doi.org/10.20517/2394-4722.2018.19
by HGF at 24 (P < 0.001) and 48 h (P < 0.001) when compared to untreated control cells, yet interestingly 
there was no significant difference between concentrations of HGF or time points, suggesting that the c-Met 
receptor or downstream signaling pathways have reached saturation point at 10 ng/mL.
It can also be seen from Figure 1C that 48 h HGF stimulation at 50 and 100 ng/mL significantly increased 
CAHPV-10 invasion through an artificial basement membrane (P < 0.042 and P < 0.019 respectively) with an 
approximate 2-fold increase in cell numbers crossing the artificial membrane compared to untreated con-
trols. These results show that exposing PCa cells, derived from a localised tumour, to HGF increases not only 
their proliferation but also their invasive capacity. 
HGF induced cell scattering in non-invasive cancer cells 
To determine whether HGF stimulation could induce cell scattering in a non-invasive cell line, we exposed 
CAHPV-10 cells (grown in small colonies) to various concentrations of HGF over 24 and 48 h time period. 
As many studies have shown HGF induce cell scattering in DU145 PCa cells, we also used DU145 cells with 
and without HGF exposure as a positive and negative controls. 
Concentrations of HGF ranged from 0-100 ng/mL. CAHPV-10 cells treated over a 24 h period did not show 
any significant signs of cell dissociation, spreading or motility. In contrast, following 48 h exposure to HGF, 
cell dissociation, spreading and motility became evident at 50 and 100 ng/mL HGF [Figure 2]. 
ARF6 is expressed in PCa cells 
A role for the GTPase ARF6 has been implicated in several cancers but information pertaining to its role in 
PCa is scant. Gene expression analysis on prostate cells derived from normal prostate epithelium through to 
aggressive, metastatic disease revealed ARF6 to be present in prostate cells [Figure 3A]. There was no signifi-
Figure 1. HGF significantly increased the proliferation of CAHPV-10 non-invasive prostate cancer cells over (A) 24 h and (B) 48 h. 
CAHPV-10 cells were serum starved for 24 h before exposure to HGF. The data are expressed as mean ± standard deviation (SD) (from 
4 replicates repeated in triplicate). *Denotes significant difference between treated and control cells (P  < 0.05); C: HGF significantly 
increased the invasive capacity of CAHPV-10 cells. Cells were seeded onto an artificial basement membrane extract in transwell inserts 
and serum starved for 24 h before treatment with HGF for 48 h. The data are expressed as mean (from triplicate experiments) ± SD. 
*Denotes significant difference between treated and control cells (P  < 0.05). HGF: hepatocyte growth factor
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cant difference in ARF6 levels when CAHPV-10 were compared to the normal prostate cell line PNT2 but 
there was a significant difference between non-invasive and invasive cancer cells. ARF6 levels were signifi-
cantly higher in LNCaP (3.9-fold), DU145 (3.3-fold) and PC-3 (4.3-fold) cells compared to CAHPV-10 (P < 0.04, 
0.032 and 0.009 respectively). There was no significant difference between the invasive cell lines regardless of 
their differing invasive capacities. 
To determine whether mRNA levels were translated through to the protein level, we then performed western 
blot analysis. Protein bands correlating to ARF6 were evident in all samples [Figure 3A] but densitometry 
[Figure 3C] revealed total levels of ARF6 were not significantly different between PNT2 (1.37) and CAH-
PV-10 cells (1.21) yet were significantly increased in the metastatic cell lines LNCaP, 5.92 and PC-3, 3.26 (P < 
0.001 and P < 0.034 respectively). 
Immunofluorescence shows ARF6 localises to the plasma membrane in aggressive cancer cells
Inactive ARF6 (ARF-GDP) localises to the cytosol and endosomes and when activated (ARF-GTP) translo-
cates to the plasma membrane. Therefore, we carried out immunofluorescence to ascertain the localisation 
of ARF6 in all our PCa cells. Figure 4 shows that staining for ARF6 was predominantly localised to the cell 
Figure 2. CAHPV-10 non-invasive prostate cancer cells treated with (A) control (PBS + medium); B: 10 ng/mL HGF; C: 25 ng/mL HGF; D: 
50 ng/mL HGF; E: 100 ng/mL HGF for 48 h; F: DU145 cells treated with 10 ng/mL for 48 h as a positive control; G: DU145 cells without 
HGF for 48 h as a negative control. Scale bar (shown in A) represents 25µ mol/L for (A-C) and 50µ mol/L for D-G
A B C
D E F
G
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periphery in all cell types. In PNT2 cells, ARF6 staining intensity was very weak but intensity increased with 
progression to an aggressive phenotype suggesting higher levels of the activated form of ARF6 is present at 
Figure 3. A: Gene expression analysis shows ARF6 is expressed in prostate cells derived from normal tissue (PNT2), localised prostate 
cancer (CAHVP-10), weakly metastatic (LNCaP), moderately (DU145) and aggressively (PC-3) metastatic prostate cancer tissue. ARF6 
expression was similar between PNT2 and CAHPV-10. A significant increase in expression was observed in LNCaP, DU145 and PC-3 
compared to CAHPV-10. The data are expressed as mean (from triplicate experiments), relative to PNT2, ± SD. *Denotes significant 
difference compared to PNT2 (P  < 0.05); B: western blot analysis for total ARF6 protein; C: densitometry data is presented relative to the 
level of β-actin. The data are expressed as mean (from triplicate experiments) ± SD
PNT2                                             CAHPV-10                                      LNCaP                                     DU145                                            PC3
Figure 4. Inactive ARF6 localises to the cytosol and endosomes and when activated translocates to the plasma membrane. Representative 
immunofluorescence images show cells stained with rabbit anti-ARF6 exhibit a stronger signal intensity at the plasma membrane in the 
metastatic cell lines (LNCaP, DU145, PC3) than those derived from normal tissue (PNT2) and localised prostate cancer (CAHPV-10). 
Corresponding negative controls are shown in the bottom row
A
B C
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the cell membrane in cells with an invasive phenotype compared to cells which are derived from normal 
prostate epithelium or non-invasive cancer tissue. 
Active ARF6 can be detected in aggressive PCa cells
To quantify levels of ARF-GTP, we performed a GTP pull down assay, which utilises a fusion protein GST-
GGA3 that specifically interacts with the GTP bound form of ARF6. This was performed on all prostate cells 
representing normal through to aggressive metastatic disease. Western blot analysis of ARF6-GTP and total 
ARF6 can be seen in Figure 5A, which shows ARF6-GTP to be evident in the invasive cell lines whilst very 
low levels were observed in the non-invasive cells. Densitometry was performed and a ratio between ARF6-
GTP and total levels of ARF6 were calculated. Figure 5B shows levels of ARF6-GTP were significantly higher 
in LNCaP (P < 0.033) and PC3 (P < 0.034) compared to non-cancerous prostate cells (PNT2). Furthermore, 
ARF6-GTP levels in LNCaP and PC-3 were significantly higher (> 2.5 fold) than in the localised prostate 
cells CAHPV10 (P < 0.044 and 0.001 respectively). 
HGF induces the activation of ARF6 in non-invasive cells 
HGF is known to activate ARF6, therefore we wished to determine whether HGF stimulation could activate 
ARF6 in the non-invasive CAHPV-10 cells. Fifty nanograms per millilitre was the lowest concentration that 
produced a significant effect on cell invasion and a discernable effect on cell scattering, thus, we chose these 
parameters to stimulate the CAHPV10 cells. 
Western blot analysis revealed that the active form of ARF6 was substantially elevated in HGF treated cells 
compared to BSA/PBS treated control cells so much so that when not stimulated with HGF no discernible 
Figure 5. A: GST pull down assay for ARF6-GTP was performed on prostate cells from normal prostate (PNT2), localised prostate 
cancer (CAHVP-10), weakly metastatic (LNCaP), moderately (DU145) and aggressively (PC-3) metastatic prostate cancer. Twenty five 
microlitres of GST assay elute was used in western blot analysis for ARF6-GTP detection. A: corresponding 25 µL aliquot from total 
protein lysis was used for detection of total ARF6 protein; B: band density was measured by densitometry and the ratios of ARF6-GTP to 
total ARF6 are shown. The data are expressed as mean (from triplicate experiments) ± SD. *Denotes significant difference compared to 
PNT2 (P  < 0.05)
A
B
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band could be detected but after HGF stimulation ARF6 detection was abundantly expressed [Figure 6]. 
DISCUSSION 
While not standard of care, the use of ADT as an early stage treatment option is becoming increasingly 
important[2]. To mimic the possible effect of neo-adjuvant ADT in early PCa we stimulated a noninvasive 
cell line, known to express c-Met, with HGF. Our results revealed that HGF stimulation induced cell prolif-
eration, scattering and cell invasion as well as activating ARF6. All of these processes are associated in one 
way or another with enhancing the aggressive nature of cancer cells and/or are essential components of the 
metastatic cascade. Cell proliferation was significantly increased in HGF stimulated cells when compared 
to untreated cells following both 24 and 48 h exposure. This finding is not surprising given that HGF plays 
an essential role in embryonic development and wound healing[33]. However, HGF stimulation did not pro-
duce a time or concentration dependent effect. We hypothesise that this effect is due to the c-MET receptor, 
or downstream pathways, reaching saturation point at 10 ng/mL and thus, any increases in concentration 
or length of time has no additional effect on cell proliferation. This is supported by other studies that have 
shown that changes in HGF and c-MET levels do not always invoke a concentration-dependent response ei-
ther due to variants in HGF or c-Met or that down-stream signalling pathways become saturated and can no 
longer be phosphorylated[34].
Interestingly HGF also caused these non-invasive cells to scatter when compared to untreated control cells. 
HGF has been shown to cause the disruption of a variety of normal epithelial cells resulting in cell migra-
tion[35] necessary for wound healing but it is also an essential attribute in the metastatic phenotype. HGF has 
been shown to induce cell scattering by inhibiting E-cadherin function resulting in cell-cell dissociation[36], 
the disassembly of cell-cell adhesion complexes[37] and activation of the Ras/MAPK[38] and PI-3 kinase[39] 
pathways. Our results showed that HGF only induced cell dissociation, spreading and motility at the higher 
concentrations (50 and 100 ng/mL at 48 h). HGF is typically a paracrine factor, expressed by mesenchyme 
to activate c-MET in the neighbouring epithelia. Studies have shown that stromal cells secrete HGF in the 
range of 14-24 ng/mL[34]. Studies have also reported that serum levels increase as PCa progresses with one 
study showing that serum HGF levels in metastatic cancer patients were 2 times that of localised PCa pa-
tients[17]. Thus, in vitro HGF stimulation at high concentrations could possibly mimic the higher levels seen 
in the tumour microenvironment as a result of ADT and account for the observed phenotypic effects on cell 
dissociation. 
It has been well documented that HGF stimulation enhances prostate tumour cell invasion in vitro[9,19,40,41] 
while blocking the expression of c-Met reverses the invasive properties of PCa cells[40,42]. Using 50 ng/mL 
HGF for 48 h we observed a significant increase in the invasive capacity of the CAHPV-10 cells compared 
to un-stimulated control cells. It may be suggested that an increase in cell proliferation may account for 
HGF (ng/mL)
0                            50
ARF6-GTP
Total ARF6
Figure 6. HGF activates ARF6. CAHPV-10 cells were serum starved for 24 h before being exposed to 50 ng/mL HGF for 48 h. Active 
ARF6 pull down assay and western blot analysis shows activated ARF6 to be present in HGF treated cells but not in untreated control 
cells
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the increased number of cells invading through an artificial basement membrane matrix. However, in our 
cell proliferation studies, significant increases in cell proliferation were seen at 10 ng/mL of HGF while the 
number of cells invading through the artificial membrane only significantly increased at 50 ng/mL. Thus, we 
believe that if the results of the invasion assay could be influenced by an increase in cell proliferation then 
we would have observed a significant number of cells invading the basement membrane at 10 ng/mL Thus, 
unlike in previous studies that use cell lines that already have metastatic capabilities, we have shown, for 
the first time that treating non-invasive PCa cells with HGF can induce an invasive phenotype. Building on 
from this finding future work would will need to expanded the range of cell types used to include more non-
invasive PCa cell lines to achieve a more rounded representation of “PCa”[43].
ARF6 is a member of the Ras superfamily and can be activated by various growth factors, in particular, by 
HGF[28]. It functions in a range of biological activities and has be shown to play roles in adherens junction 
disassembly[26], cell migration[44] and cell proliferation[45]. While there is very little information on the pres-
ence or activation of ARF6 in PCa we have recently shown that ARF proteins are over-expressed in PCa 
tissue compared to normal control tissue[31]. In this study, gene expression analysis revealed that ARF6 is 
expressed in all the prostate cells. Analysis showed that there was no significant difference in expression 
between cells derived from normal prostate epithelium and localised, non-invasive PCa but a significant 
difference in expression between non-invasive and invasive cancer cells was evident. ARF6 levels were sig-
nificantly higher in LNCaP, DU145 and PC-3 cells compared to CAHPV-10 but there was no significant dif-
ference between the invasive cell lines regardless of their differing invasive capacities. Protein analysis con-
firmed the gene expression data and showed that ARF6 protein was detectable in all prostate cells. Like the 
majority of GTPases, ARF6 cycles between an inactive GDP-bound form and an active GTP-bound form[28]. 
Inactive ARF6 localises to the cytosol and endosomes and when activated it translocates to the plasma mem-
brane[46]. Immunofluorescence revealed a strong defined signal at the periphery of the cells in both DU145 
and PC-3 indicating a close association of ARF6 and the cell membrane while staining intensity appeared to 
be markedly reduced in both CAHPV-10, and PNT2. This data would appear to suggest that activated ARF6 
increases with the aggressiveness of the cancer. To validate the immunofluorescence data, Western blotting 
and densitometry analysis of ARF6-GTP and total ARF6 were performed. ARF6-GTP was shown to be evi-
dent in the invasive cell lines but very low levels in the non-invasive cell lines. The ratio between ARF6-GTP 
and total levels of ARF6 were also calculated and highlighted the fact that levels of ARF6-GTP were higher 
in all the cells derived from invasive tumours. In particular, in the cell line PC-3, which is a cell line derived 
from a highly aggressive PCa that has metastasised to the bone and is representative of the main metastatic 
site for PCa, ARF6-GTP levels were found to be 3.5 and 2.7 times higher than the levels found in normal and 
non-invasive cells respectively. 
It has been documented that HGF can activate ARF6 in epithelial cells[26]. As neo-adjuvant ADT can in-
crease the levels of HGF, we wanted to determine whether HGF stimulation could activate ARF6 in the non-
invasive cell line CAHPV-10. Using 50 ng/mL for 48 h we found that activated ARF6 levels increased com-
pared to untreated CAHPV-10 cells. ARF6 plays an essential role in epithelial and endothelial cell migration 
and elevated levels of activated ARF6 have been found to increase the invasive capacity of melanoma cells 
both in vitro[28] and in vivo[29], while silencing ARF6 has been shown to inhibit the ability of breast cancer 
cells to invade through an artificial basement membrane[30]. Whether HGF stimulated activation of ARF6 is 
responsible for the increased proliferation, motility and invasiveness observed following HGF stimulation of 
CAHPV-10 cells now needs to be determined. 
In conclusion, ADT is increasingly being used in the neo-adjuvant setting. With the importance of HGF and 
cMet in PCa documented, it has been hypothesised that while current ADT may inhibit AR mediated cell 
proliferation and survival, it may abolish its suppressive role on the HGF/c-Met pathway, unintentionally 
driving tumour progression. We have shown that HGF enhanced cell proliferation, induced scattering and 
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cell invasion in a non-invasive cell line. We have shown that ARF6 is expressed in non-invasive PCa cells 
and that HGF stimulation correlates with increased levels of activated ARF6. All of these processes are asso-
ciated with enhancing the aggressive nature of cancer cells. While further work is now needed to determine 
whether HGF activation of ARF6 is responsible for driving the cellular changes observed in this study, and 
on additional non-invasive cell lines, these findings provide further molecular insight into the progression of 
PCa and would suggest that ADT is unintentionally driving PCa through increasing levels of active ARF6. 
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